LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1183-1188

  Švihálková Šindlerová, Lenka ^a   Foltinová, Vendula ^b   Vaculová, Alena ^a   Horváth, Viktor ^a   Souček, Karel ^a   Sova, Petr ^c   Hofmanová, Jiřina ^a   Kozubík, Alois ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c R and D   (Czech Republic)

Author keywords

Apoptosis; Cell cycle; Cisplatin; Colon cancer; LA 12; Oxaliplatin

Indexed keywords

CISPLATIN; DIMETHYL SULFOXIDE; EOSIN; LA 12; LIPOCORTIN 5; OXALIPLATIN; PLATINUM DERIVATIVE; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE; CELL POPULATION; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; WESTERN BLOTTING;

ADENOCARCINOMA; AMANTADINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CISPLATIN; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 77953770448     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ho YP and Au-Yeung SC and To KK: Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 23: 633-655, 2003.
2. Muggia FM and Fojo T: Platinums: extending their therapeutic spectrum. J Chemother 16(Suppl 4): 77-82, 2004.
3. Wong E and Giandomenico CM: Current status of platinum-based antitumor drugs. Chem Rev 99: 2451-2466, 1999.
4. Levi F and Metzger G, Massari C and Milano G: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38: 1-21, 2000.
5. Horváth V and Blanářová O, Švihálková-Šindlerová L, Souček K, Hofmanová J, Sova P, Kroutil A, Fedoročko P and Kozubík A: Platinum (IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecologic Oncology 702: 32-40, 2006.
6. Kozubík A and Horváth V, Šviháková- Šindlerová L, Souček K, Hofmanová J, Sova P, Kroutil A, Žák F, Mistr A and Turánek J: High effectiveness of platinum (IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69: 373-383, 2005.
7. Turánek J and Kašná A, Záluská D, Neča J, Kvardová V, Knötigová P, Horváth V, Šindlerová L, Kozubík A, Sova P, Kroutil A, Žák F and Mistr A: New platinum (IV) complex with adamantylamine ligand as a promising anticancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anticancer Drugs 75: 537-543, 2004.
8. Cermanová J and Chládek J, Sova P, Kroutil A, Semerád M, Beránková Z, Široký P and Súrová I: Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamme]amminedichloroplatinum [IV]) in pigs. Methods Find Exp Clin Pharmacol 26: 679-685, 2004.
9. Sova P and Chládek J, Žak F, Mistr A, Kroutil A, Semerád M and Slovák Z: Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV)]. Int J Pharm 288: 123-129, 2005.
10. Sova P and Mistr A, Kroutil A, Žák F, Pouč ková P and Zadinová M: Comparative anti-tumor efficacy of two orally administered platinum (IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs 77: 201-206, 2006.
11. Milner AE and Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ, Young LS: Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ 9: 287-300, 2002.
12. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
13. Dimanche-Boitrel MT and Pelletier H, Genne P, Petit JM, Le Grimellec C, Canal P, Ardiet C, Bastian G and Chauffert B: Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 50: 677-682, 1992.
14. Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B and Mehlen P: HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 57: 2661-2667, 1997.
15. Dimanche-Boitrel MT and Garrido C and Chauffert B: Kinetic resistance to anticancer agents. Cytotechnology 72: 347-356, 1993.
16. Švihálková-Šindlerová L and Machala M, Pěnčíková K, Marvanová S, Neča J, Topinka J, Sevastyanova O, Kozubík A and Vondráček J: Dibenzanthracenes and benzochrysenes elicit both genotoxic and nongenotoxic events in rat liver 'stem-like' cells. Toxicology 232: 147-159, 2007.
17. Vaculová A and Hofmanová J, Anděra L and Kozubík A: TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death. Cancer Lett 229: 43-48, 2005.
18. O'Brien CA and Kreso A and Dick JE: Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 79: 71-77, 2009.
19. Pucci B and Kasten M and Giordano A: Cell cycle and apoptosis. Neoplasia 2: 291-299, 2000.
20. Wang JY: DNA damage and apoptosis. Cell Death Differ 8: 1047-1048, 2001.
21. Montalenti F and Sena G, Cappella P and Ubezio P: Simulating cancer-cell kinetics after drug treatment: application to cisplatin on ovarian carcinoma. Physical Review E 57: 5877, 1998.
22. Sekiguchi I and Suzuki M, Tamada T, Shinomiya N, Tsuru S and Murata M: Effects of cisplatin on cell cycle kinetics, morphological change, and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Oncology 53: 19-26, 1996. (Pubitemid 26025232)
23. Arnould S and Guichard S, Hennebelle I, Cassar G, Bugat R and Canal P: Contribution of apoptosis in the cytotoxicity of oxaliplatin-irinotecan combination in the HT-29 human colon adenocarcinoma cell line. Biochemical Pharmacology 64: 1215-1226, 2002.
24. Roubalová E: The effects of the cytostatic drug LA-12 on p53 stability and activity in human tumour cells. Masaryk University, Faculty of Science Brno, Institute of Experimental Biology, pp. 1-49, 2007 (in Czech).
25. Hrstka R and Powell DJ, Kvardová V, Roubalová E, Bourougaa K, Candeias MM, Sova P, Žák F, Fahraeus R and Vojtěš ek B: The novel platinum (IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs 79: 369-379, 2008.